Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1992 Dec 12;305(6867):1470–1473. doi: 10.1136/bmj.305.6867.1470

Regional transfusion centre preoperative autologous blood donation programme: the first two years.

M R Howard 1, C E Chapman 1, J A Dunstan 1, C Mitchell 1, H L Lloyd 1
PMCID: PMC1884093  PMID: 1493393

Abstract

OBJECTIVE--To assess the efficacy of a regional autologous blood donation programme. DESIGN--Clinical and laboratory data were collected and stored prospectively. Transfusion data were collected retrospectively from hospital blood bank records. SETTING--Northern Region Blood Transfusion Service and 14 hospitals within the Northern Regional Health Authority. SUBJECTS--505 patients referred for autologous blood donation before elective surgery. MAIN OUTCOME MEASURES--Patient eligibility, adverse events from donation, autologous blood units provided, and autologous and allogeneic blood units transfused within 10 days of operation. RESULTS--Of 505 patients referred, 354 donated at least one unit. 78 of 151 referred patients who did not donate were excluded at the autologous clinic, mostly because of anaemia or ischaemic heart disease. In 73 cases the patient, general practitioner, or hospital consultant decided against donation. 363 autologous procedures were undertaken. In 213 (59%) cases all requested units were provided. The most common reasons for incomplete provision were late referral or anaemia. Adverse events accompanied 24 of 928 donations (2.6%). Transfusion data were obtained for 357 of the 363 procedures. 281 donors were transfused; autologous blood only was given to 225, autologous and allogeneic blood was given to 52, and allogeneic blood only was given to four. 648 of 902 (72%) units of autologous blood were transfused. Complete provision of requested autologous units was followed by allogeneic transfusion in 12 of 208 procedures (5.8%). Incomplete provision was followed by allogeneic transfusion in 44 of 149 procedures (30%). CONCLUSIONS--This study shows the feasibility of a regional autologous transfusion programme. Autologous donors only infrequently received allogeneic transfusion. Patients should be appropriately selected and referred early.

Full text

PDF
1470

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AuBuchon J. P., Popovsky M. A. The safety of preoperative autologous blood donation in the nonhospital setting. Transfusion. 1991 Jul-Aug;31(6):513–517. doi: 10.1046/j.1537-2995.1991.31691306248.x. [DOI] [PubMed] [Google Scholar]
  2. Dodd R. Y. The risk of transfusion-transmitted infection. N Engl J Med. 1992 Aug 6;327(6):419–421. doi: 10.1056/NEJM199208063270610. [DOI] [PubMed] [Google Scholar]
  3. Donahue J. G., Muñoz A., Ness P. M., Brown D. E., Jr, Yawn D. H., McAllister H. A., Jr, Reitz B. A., Nelson K. E. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992 Aug 6;327(6):369–373. doi: 10.1056/NEJM199208063270601. [DOI] [PubMed] [Google Scholar]
  4. Giblett E. R. Blood group alloantibodies: an assessment of some laboratory practices. Transfusion. 1977 Jul-Aug;17(4):299–308. doi: 10.1046/j.1537-2995.1977.17477216857.x. [DOI] [PubMed] [Google Scholar]
  5. Goodnough L. T., Rudnick S., Price T. H., Ballas S. K., Collins M. L., Crowley J. P., Kosmin M., Kruskall M. S., Lenes B. A., Menitove J. E. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989 Oct 26;321(17):1163–1168. doi: 10.1056/NEJM198910263211705. [DOI] [PubMed] [Google Scholar]
  6. Graf H., Watzinger U., Ludvik B., Wagner A., Höcker P., Zweymüller K. K. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. BMJ. 1990 Jun 23;300(6740):1627–1628. doi: 10.1136/bmj.300.6740.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gunson H. H., Rawlinson V. I. Screening of blood donations for HIV-1 antibody: 1985-1991. CDR (Lond Engl Rev) 1991 Dec 6;1(13):R144–R146. [PubMed] [Google Scholar]
  8. Hickman M., Mortimer J. Y., Rawlinson V. I. Donor screening for HIV: how many false negatives? Lancet. 1988 May 28;1(8596):1221–1221. doi: 10.1016/s0140-6736(88)92032-6. [DOI] [PubMed] [Google Scholar]
  9. Kruskall M. S., Glazer E. E., Leonard S. S., Willson S. C., Pacini D. G., Donovan L. M., Ransil B. J. Utilization and effectiveness of a hospital autologous preoperative blood donor program. Transfusion. 1986 Jul-Aug;26(4):335–340. doi: 10.1046/j.1537-2995.1986.26486262740.x. [DOI] [PubMed] [Google Scholar]
  10. Pindyck J., Avorn J., Kuriyan M., Reed M., Iqbal M. J., Levine S. J. Blood donation by the elderly. Clinical and policy considerations. JAMA. 1987 Mar 6;257(9):1186–1188. [PubMed] [Google Scholar]
  11. Popovsky M. A., Chaplin H. C., Jr, Moore S. B. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion. 1992 Jul-Aug;32(6):589–592. doi: 10.1046/j.1537-2995.1992.32692367207.x. [DOI] [PubMed] [Google Scholar]
  12. Schmidt P. J. Blood donation by the healthy elderly. Transfusion. 1991 Oct;31(8):681–683. doi: 10.1046/j.1537-2995.1991.31892023489.x. [DOI] [PubMed] [Google Scholar]
  13. Tasaki T., Ohto H., Hashimoto C., Abe R., Saitoh A., Kikuchi S. Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production. Lancet. 1992 Mar 28;339(8796):773–775. doi: 10.1016/0140-6736(92)91895-f. [DOI] [PubMed] [Google Scholar]
  14. Toy P. T., Strauss R. G., Stehling L. C., Sears R., Price T. H., Rossi E. C., Collins M. L., Crowley J. P., Eisenstaedt R. S., Goodnough L. T. Predeposited autologous blood for elective surgery. A national multicenter study. N Engl J Med. 1987 Feb 26;316(9):517–520. doi: 10.1056/NEJM198702263160906. [DOI] [PubMed] [Google Scholar]
  15. Ward J. W., Holmberg S. D., Allen J. R., Cohn D. L., Critchley S. E., Kleinman S. H., Lenes B. A., Ravenholt O., Davis J. R., Quinn M. G. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med. 1988 Feb 25;318(8):473–478. doi: 10.1056/NEJM198802253180803. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES